Ligand source activities (1 row/activity)



Get vendors


Ligands Receptor Assay information Chemical information
Sel. page Common
name		 GPCRdb ID #Vendors Reference
ligand		 Fold selectivity
(Potency)		 # tested GPCRs
(Potency)		 Species p-value
(-log)		 Type Activity
Relation		 Activity
Value		 Assay Type Assay Description Source Mol
weight		 Rot
Bonds		 H don H acc LogP Smiles DOI
10180382 110535 0 None 1 2 Human 5.9 pEC50 = 5.9 Functional
Agonistic activity against lysophosphatidic acid receptor 1 receptor using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 receptor using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 419 19 4 3 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(O)P(=O)(O)O 10.1016/j.bmcl.2004.04.061
CHEMBL325288 110535 0 None 1 2 Human 5.9 pEC50 = 5.9 Functional
Agonistic activity against lysophosphatidic acid receptor 1 receptor using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 receptor using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 419 19 4 3 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(O)P(=O)(O)O 10.1016/j.bmcl.2004.04.061
156020178 178104 0 None - 1 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 446 20 2 5 5.1 CCCCCC/C=C\CCCCCCCC(=O)OC[C@H](CC(F)(C(=O)O)C(=O)O)OC 10.1021/acs.jmedchem.9b01287
CHEMBL4648374 178104 0 None - 1 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 446 20 2 5 5.1 CCCCCC/C=C\CCCCCCCC(=O)OC[C@H](CC(F)(C(=O)O)C(=O)O)OC 10.1021/acs.jmedchem.9b01287
5311263 4126 22 None -10 7 Human 7.8 pEC50 = 7.8 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1016/j.bmcl.2004.04.061
CHEMBL117021 4126 22 None -10 7 Human 7.8 pEC50 = 7.8 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1016/j.bmcl.2004.04.061
156013745 177243 0 None - 1 Human 5.8 pEC50 = 5.8 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 442 18 1 5 5.7 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H]1CC(F)(C(=O)O)C(=O)O1 10.1021/acs.jmedchem.9b01287
CHEMBL4636192 177243 0 None - 1 Human 5.8 pEC50 = 5.8 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 442 18 1 5 5.7 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H]1CC(F)(C(=O)O)C(=O)O1 10.1021/acs.jmedchem.9b01287
6610239 67585 27 None -1 2 Human 5.7 pEC50 = 5.7 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 423 19 4 4 4.1 CCCCCCCCCCCCCCCC(=O)N[C@@H](COP(=O)(O)O)C(=O)O 10.1021/jm049609r
CHEMBL190328 67585 27 None -1 2 Human 5.7 pEC50 = 5.7 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 423 19 4 4 4.1 CCCCCCCCCCCCCCCC(=O)N[C@@H](COP(=O)(O)O)C(=O)O 10.1021/jm049609r
156011290 177350 0 None - 1 Human 4.7 pEC50 = 4.7 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 520 19 3 5 6.2 O=C(CCCCCCCCCCCCc1ccc(-c2ccccc2)cc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4637898 177350 0 None - 1 Human 4.7 pEC50 = 4.7 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 520 19 3 5 6.2 O=C(CCCCCCCCCCCCc1ccc(-c2ccccc2)cc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
11473989 67091 0 None 1 3 Human 6.7 pEC50 = 6.7 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 364 17 2 2 6.3 CCCCCCCC/C=C/CCCCCCCCOP(O)(O)=S 10.1021/jm049609r
CHEMBL187459 67091 0 None 1 3 Human 6.7 pEC50 = 6.7 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 364 17 2 2 6.3 CCCCCCCC/C=C/CCCCCCCCOP(O)(O)=S 10.1021/jm049609r
44344023 113309 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 403 19 3 2 5.7 CCCCCCCC/C=C\CCCCCCCC(=O)NCCCP(=O)(O)O 10.1016/j.bmcl.2004.04.061
CHEMBL331661 113309 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 403 19 3 2 5.7 CCCCCCCC/C=C\CCCCCCCC(=O)NCCCP(=O)(O)O 10.1016/j.bmcl.2004.04.061
44343825 11029 24 None -6 2 Human 6.7 pEC50 = 6.7 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 405 19 3 3 5.2 CCCCCCCC/C=C\CCCCCCCC(=O)NCCOP(=O)(O)O 10.1016/j.bmcl.2004.04.061
CHEMBL117754 11029 24 None -6 2 Human 6.7 pEC50 = 6.7 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 405 19 3 3 5.2 CCCCCCCC/C=C\CCCCCCCC(=O)NCCOP(=O)(O)O 10.1016/j.bmcl.2004.04.061
5283533 177069 1 None - 1 Human 5.7 pEC50 = 5.7 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 422 19 3 5 4.6 CCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4633208 177069 1 None - 1 Human 5.7 pEC50 = 5.7 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 422 19 3 5 4.6 CCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156016950 177730 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 388 14 3 5 3.0 O=C(CCCCCCCCc1ccccc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4642688 177730 0 None - 1 Human 5.7 pEC50 = 5.7 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 388 14 3 5 3.0 O=C(CCCCCCCCc1ccccc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
10136738 10995 0 None 5 2 Human 6.7 pEC50 = 6.7 Functional
Agonist activity at LPA1R (unknown origin) by [35S]GTPgammaS binding assayAgonist activity at LPA1R (unknown origin) by [35S]GTPgammaS binding assay
ChEMBL 417 19 3 3 5.2 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=O)P(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL117529 10995 0 None 5 2 Human 6.7 pEC50 = 6.7 Functional
Agonist activity at LPA1R (unknown origin) by [35S]GTPgammaS binding assayAgonist activity at LPA1R (unknown origin) by [35S]GTPgammaS binding assay
ChEMBL 417 19 3 3 5.2 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=O)P(=O)(O)O 10.1021/acs.jmedchem.9b01287
10136738 10995 0 None 5 2 Human 6.7 pEC50 = 6.7 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 417 19 3 3 5.2 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=O)P(=O)(O)O 10.1016/j.bmcl.2004.04.061
CHEMBL117529 10995 0 None 5 2 Human 6.7 pEC50 = 6.7 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 417 19 3 3 5.2 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=O)P(=O)(O)O 10.1016/j.bmcl.2004.04.061
10587 3877 4 None - 1 Human 6.6 pEC50 = 6.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 BrC[C@@H](OC(=O)CCCCCCCCCc1ccccc1)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
145996523 3877 4 None - 1 Human 6.6 pEC50 = 6.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 BrC[C@@H](OC(=O)CCCCCCCCCc1ccccc1)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4646737 3877 4 None - 1 Human 6.6 pEC50 = 6.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 BrC[C@@H](OC(=O)CCCCCCCCCc1ccccc1)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156017427 177746 0 None - 1 Human 6.6 pEC50 = 6.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 O=C(CCCCCCCCCc1ccccc1)OC(CBr)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4642952 177746 0 None - 1 Human 6.6 pEC50 = 6.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 O=C(CCCCCCCCCc1ccccc1)OC(CBr)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156017791 177792 0 None - 1 Human 4.6 pEC50 = 4.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 O=C(CCCCCCCCCc1ccccc1)O[C@@H](CBr)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4643694 177792 0 None - 1 Human 4.6 pEC50 = 4.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 464 15 2 4 4.8 O=C(CCCCCCCCCc1ccccc1)O[C@@H](CBr)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
52929768 178030 0 None - 1 Human 5.6 pEC50 = 5.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 380 16 3 5 3.5 CCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4647245 178030 0 None - 1 Human 5.6 pEC50 = 5.6 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 380 16 3 5 3.5 CCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
5311263 4126 22 None -10 7 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at LPA1 expressed in human chem1 cells assessed as intracellular calcium mobilization by FLIPR assayAgonist activity at LPA1 expressed in human chem1 cells assessed as intracellular calcium mobilization by FLIPR assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1016/j.bmc.2009.12.020
CHEMBL117021 4126 22 None -10 7 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at LPA1 expressed in human chem1 cells assessed as intracellular calcium mobilization by FLIPR assayAgonist activity at LPA1 expressed in human chem1 cells assessed as intracellular calcium mobilization by FLIPR assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1016/j.bmc.2009.12.020
44343851 110649 0 None - 1 Human 6.5 pEC50 = 6.5 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 433 19 3 3 6.0 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=S)P(=O)(O)O 10.1016/j.bmcl.2004.04.061
CHEMBL325970 110649 0 None - 1 Human 6.5 pEC50 = 6.5 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 433 19 3 3 6.0 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=S)P(=O)(O)O 10.1016/j.bmcl.2004.04.061
156011890 177317 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 498 20 2 4 6.4 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@H](CBr)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4637403 177317 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 498 20 2 4 6.4 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@H](CBr)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156019757 177923 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 416 16 3 5 3.8 O=C(CCCCCCCCCCc1ccccc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4645684 177923 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 416 16 3 5 3.8 O=C(CCCCCCCCCCc1ccccc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156018702 177871 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 478 16 3 5 5.0 O=C(CCCCCCCCCc1ccc(-c2ccccc2)cc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4644847 177871 0 None - 1 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 478 16 3 5 5.0 O=C(CCCCCCCCCc1ccc(-c2ccccc2)cc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
5311263 4126 22 None -10 7 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human LPA1 expressed in LPA1xLPA2 double knockout mouse MEF cells up to 10 uM by Fura-2AM dye based Ca2+ mobilization assayAgonist activity at human LPA1 expressed in LPA1xLPA2 double knockout mouse MEF cells up to 10 uM by Fura-2AM dye based Ca2+ mobilization assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/jm5007116
CHEMBL117021 4126 22 None -10 7 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human LPA1 expressed in LPA1xLPA2 double knockout mouse MEF cells up to 10 uM by Fura-2AM dye based Ca2+ mobilization assayAgonist activity at human LPA1 expressed in LPA1xLPA2 double knockout mouse MEF cells up to 10 uM by Fura-2AM dye based Ca2+ mobilization assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/jm5007116
44159681 177039 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 450 21 3 5 5.4 CCCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4632820 177039 0 None - 1 Human 5.4 pEC50 = 5.4 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 450 21 3 5 5.4 CCCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
129836 177982 19 None - 1 Human 5.4 pEC50 = 5.4 Functional
Agonist activity at recombinant human full-length LPA1 receptor expressed in dhfr- deficient CHO cells assessed as increase in intracellular calcium flux measured for 1 min by fluo-3AM dye based FLIPR assayAgonist activity at recombinant human full-length LPA1 receptor expressed in dhfr- deficient CHO cells assessed as increase in intracellular calcium flux measured for 1 min by fluo-3AM dye based FLIPR assay
ChEMBL 254 0 1 1 3.7 CC1CCC2(C)c3[nH]c4ccccc4c3CCN2C1 10.1021/acs.jmedchem.9b01287
CHEMBL4646443 177982 19 None - 1 Human 5.4 pEC50 = 5.4 Functional
Agonist activity at recombinant human full-length LPA1 receptor expressed in dhfr- deficient CHO cells assessed as increase in intracellular calcium flux measured for 1 min by fluo-3AM dye based FLIPR assayAgonist activity at recombinant human full-length LPA1 receptor expressed in dhfr- deficient CHO cells assessed as increase in intracellular calcium flux measured for 1 min by fluo-3AM dye based FLIPR assay
ChEMBL 254 0 1 1 3.7 CC1CCC2(C)c3[nH]c4ccccc4c3CCN2C1 10.1021/acs.jmedchem.9b01287
44343866 11060 0 None 2 2 Human 7.4 pEC50 = 7.4 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 433 19 3 3 5.4 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=O)P(O)(O)=S 10.1016/j.bmcl.2004.04.061
CHEMBL117798 11060 0 None 2 2 Human 7.4 pEC50 = 7.4 Functional
Agonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitroAgonistic activity against lysophosphatidic acid receptor 1 using [35S]GTP-gamma-S as radioligand tested in vitro
ChEMBL 433 19 3 3 5.4 CCCCCCCC/C=C\CCCCCCCC(=O)NCCC(=O)P(O)(O)=S 10.1016/j.bmcl.2004.04.061
52929751 177764 0 None - 1 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 408 18 3 5 4.3 CCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4643262 177764 0 None - 1 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 408 18 3 5 4.3 CCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156011219 177264 0 None - 1 Human 6.3 pEC50 = 6.3 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 402 15 3 5 3.4 O=C(CCCCCCCCCc1ccccc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL4636453 177264 0 None - 1 Human 6.3 pEC50 = 6.3 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 402 15 3 5 3.4 O=C(CCCCCCCCCc1ccccc1)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
156021731 178089 0 None - 1 Human 5.3 pEC50 = 5.3 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 445 20 3 4 4.6 CCCCCC/C=C\CCCCCCCC(=O)NC[C@H](CC(F)(C(=O)O)C(=O)O)OC 10.1021/acs.jmedchem.9b01287
CHEMBL4648051 178089 0 None - 1 Human 5.3 pEC50 = 5.3 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 445 20 3 4 4.6 CCCCCC/C=C\CCCCCCCC(=O)NC[C@H](CC(F)(C(=O)O)C(=O)O)OC 10.1021/acs.jmedchem.9b01287
2913 346 0 None -8 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysisAgonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysis
ChEMBL 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC 10.1039/C4MD00333K
56947064 346 0 None -8 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysisAgonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysis
ChEMBL 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC 10.1039/C4MD00333K
CHEMBL3621962 346 0 None -8 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysisAgonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysis
ChEMBL 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC 10.1039/C4MD00333K
156020199 178116 0 None - 1 Human 5.2 pEC50 = 5.2 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 474 22 2 5 5.9 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](CC(F)(C(=O)O)C(=O)O)OC 10.1021/acs.jmedchem.9b01287
CHEMBL4648653 178116 0 None - 1 Human 5.2 pEC50 = 5.2 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 474 22 2 5 5.9 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](CC(F)(C(=O)O)C(=O)O)OC 10.1021/acs.jmedchem.9b01287
122191543 123675 0 None -12 2 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysisAgonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysis
ChEMBL 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@H](COP(O)(O)=S)OC 10.1039/C4MD00333K
CHEMBL3621961 123675 0 None -12 2 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysisAgonist activity at human LPA1 receptor transfected in RH7777 cells assessed as mobilization of Ca2+ by fluorometric analysis
ChEMBL 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@H](COP(O)(O)=S)OC 10.1039/C4MD00333K
2906 2340 18 None -10 12 Human 7.1 pEC50 = 7.1 Functional
Agonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 10.1021/acs.jmedchem.6b01270
5395 2340 18 None -10 12 Human 7.1 pEC50 = 7.1 Functional
Agonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 10.1021/acs.jmedchem.6b01270
5497152 2340 18 None -10 12 Human 7.1 pEC50 = 7.1 Functional
Agonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 10.1021/acs.jmedchem.6b01270
CHEMBL1222042 2340 18 None -10 12 Human 7.1 pEC50 = 7.1 Functional
Agonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as increase in intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 10.1021/acs.jmedchem.6b01270
5311263 4126 22 None -10 7 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
CHEMBL117021 4126 22 None -10 7 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assayAgonist activity at LPA1 receptor (unknown origin) stably expressed in rat RH7777 cells assessed as increase in intracellular calcium level by Fluo-4 NW dye based fluorescence assay
ChEMBL 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O 10.1021/acs.jmedchem.9b01287
11317548 162346 11 None - 1 Human 9.8 pIC50 = 9.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by LPA stimulation measured after 3 mins by fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by LPA stimulation measured after 3 mins by fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4165205 162346 11 None - 1 Human 9.8 pIC50 = 9.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by LPA stimulation measured after 3 mins by fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by LPA stimulation measured after 3 mins by fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4175820 162346 11 None - 1 Human 9.8 pIC50 = 9.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by LPA stimulation measured after 3 mins by fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by LPA stimulation measured after 3 mins by fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
11317548 162346 11 None - 1 Human 9.7 pIC50 = 9.7 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by compound washout and subsequent LPA stimulation measured after 3 mins by fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by compound washout and subsequent LPA stimulation measured after 3 mins by fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4165205 162346 11 None - 1 Human 9.7 pIC50 = 9.7 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by compound washout and subsequent LPA stimulation measured after 3 mins by fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by compound washout and subsequent LPA stimulation measured after 3 mins by fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4175820 162346 11 None - 1 Human 9.7 pIC50 = 9.7 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by compound washout and subsequent LPA stimulation measured after 3 mins by fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cell membranes pretreated for 24 hrs prior to Fura-2-AM dye addition for 1 hr followed by compound washout and subsequent LPA stimulation measured after 3 mins by fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
71265339 83082 22 None - 1 Human 7.0 pIC50 = 7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 482 7 2 6 5.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
CHEMBL2182029 83082 22 None - 1 Human 7.0 pIC50 = 7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 482 7 2 6 5.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
11236547 93656 0 None 1 2 Rat 7.0 pIC50 = 7 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CCSCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246942 93656 0 None 1 2 Rat 7.0 pIC50 = 7 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CCSCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
66774612 150712 0 None 229 2 Human 7.0 pIC50 = 7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 477 12 1 5 4.8 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(OCC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3956307 150712 0 None 229 2 Human 7.0 pIC50 = 7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 477 12 1 5 4.8 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(OCC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
134156371 154318 0 None - 1 Human 7.0 pIC50 = 7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cccc(C)c3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3986868 154318 0 None - 1 Human 7.0 pIC50 = 7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cccc(C)c3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
44414925 78053 0 None 72 2 Human 7.0 pIC50 = 7.0 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 436 18 1 4 7.1 CCCCCCCCCCCCCCCCCC(=O)OC[C@@H]1CC(F)P(=O)(O)O1 10.1021/jm060351+
CHEMBL210117 78053 0 None 72 2 Human 7.0 pIC50 = 7.0 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 436 18 1 4 7.1 CCCCCCCCCCCCCCCCCC(=O)OC[C@@H]1CC(F)P(=O)(O)O1 10.1021/jm060351+
70819309 83080 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 447 7 2 5 5.5 CC(C)[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C 10.1021/jm301022v
CHEMBL2182025 83080 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 447 7 2 5 5.5 CC(C)[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C 10.1021/jm301022v
44325391 206906 0 None -30 2 Human 6.0 pIC50 = 6.0 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL91058 206906 0 None -30 2 Human 6.0 pIC50 = 6.0 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
10393842 169175 0 None 1 2 Human 7.0 pIC50 = 7.0 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL440696 169175 0 None 1 2 Human 7.0 pIC50 = 7.0 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
11409276 148720 0 None 2 2 Rat 7.0 pIC50 = 7.0 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 492 9 2 7 4.7 CC(OC(=O)Nc1conc1-c1ccc(CS(=O)(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL394038 148720 0 None 2 2 Rat 7.0 pIC50 = 7.0 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 492 9 2 7 4.7 CC(OC(=O)Nc1conc1-c1ccc(CS(=O)(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
73336174 113985 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 341 5 1 8 1.9 COc1ccc(C(=O)/C(=N\C(C)C)n2ncc(C#N)c2N)c(OC)c1 10.1016/j.bmcl.2014.08.001
CHEMBL3326534 113985 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 341 5 1 8 1.9 COc1ccc(C(=O)/C(=N\C(C)C)n2ncc(C#N)c2N)c(OC)c1 10.1016/j.bmcl.2014.08.001
71453959 83085 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1C(F)(F)F 10.1021/jm301022v
CHEMBL2182031 83085 0 None - 1 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1C(F)(F)F 10.1021/jm301022v
44441096 93606 0 None 3 2 Rat 6.9 pIC50 = 6.9 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 470 9 2 5 6.7 CC(OC(=O)Nc1conc1-c1ccc(CCC(C)(C)CC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246734 93606 0 None 3 2 Rat 6.9 pIC50 = 6.9 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 470 9 2 5 6.7 CC(OC(=O)Nc1conc1-c1ccc(CCC(C)(C)CC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
140083418 163098 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 437 11 2 5 4.9 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(C(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4177410 163098 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 437 11 2 5 4.9 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(C(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
66775429 151054 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 449 9 1 2 6.3 O=C(O)c1ccccc1-c1ccc(CN(CCCc2ccccc2)C(=O)c2ccccc2)cc1 10.1021/acsmedchemlett.6b00225
CHEMBL3959003 151054 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 449 9 1 2 6.3 O=C(O)c1ccccc1-c1ccc(CN(CCCc2ccccc2)C(=O)c2ccccc2)cc1 10.1021/acsmedchemlett.6b00225
66863259 162610 0 None - 1 Human 7.9 pIC50 = 7.9 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 451 12 2 5 4.8 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4169559 162610 0 None - 1 Human 7.9 pIC50 = 7.9 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 451 12 2 5 4.8 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
66775552 147787 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 555 13 1 6 6.5 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccccc3C(=O)O)cc2)cc(OC)c1OC 10.1021/acsmedchemlett.6b00225
CHEMBL3932828 147787 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 555 13 1 6 6.5 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccccc3C(=O)O)cc2)cc(OC)c1OC 10.1021/acsmedchemlett.6b00225
122191545 123678 0 None 17 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 1 min followed by LPA induction measured for 15 secs by Fura-2 AM probe-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 1 min followed by LPA induction measured for 15 secs by Fura-2 AM probe-based fluorometric analysis
ChEMBL 446 8 2 6 5.6 CC(OC(=O)Nc1cnoc1-c1ccc(CSCC(=O)O)cc1)c1ccccc1Cl 10.1039/C4MD00333K
CHEMBL3621965 123678 0 None 17 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 1 min followed by LPA induction measured for 15 secs by Fura-2 AM probe-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 1 min followed by LPA induction measured for 15 secs by Fura-2 AM probe-based fluorometric analysis
ChEMBL 446 8 2 6 5.6 CC(OC(=O)Nc1cnoc1-c1ccc(CSCC(=O)O)cc1)c1ccccc1Cl 10.1039/C4MD00333K
11236547 93656 0 None -1 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CCSCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246942 93656 0 None -1 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CCSCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
11316893 93845 0 None -4 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 450 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCC1 10.1016/j.bmcl.2007.04.024
CHEMBL247959 93845 0 None -4 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 450 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCC1 10.1016/j.bmcl.2007.04.024
66774300 145621 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 10 1 3 6.3 COc1cccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3915800 145621 0 None - 1 Human 5.9 pIC50 = 5.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 10 1 3 6.3 COc1cccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
134145238 150711 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 525 12 1 5 6.5 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cccc(C(=O)O)c3)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3956293 150711 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 525 12 1 5 6.5 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cccc(C(=O)O)c3)cc2)c1 10.1021/acsmedchemlett.6b00225
134156710 154075 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3c(C)cccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3984953 154075 0 None - 1 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3c(C)cccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
11167018 93607 0 None -1 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 457 8 3 6 5.1 CC(OC(=O)Nc1conc1-c1ccc(NC(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246735 93607 0 None -1 2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 457 8 3 6 5.1 CC(OC(=O)Nc1conc1-c1ccc(NC(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
132191135 158031 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAntagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 468 4 1 4 3.7 O=C(Nc1cc(F)c(F)c(F)c1)c1cc(S(=O)(=O)N2CCOCC2)c(Cl)cc1Cl 10.1021/acs.jmedchem.6b01270
CHEMBL4085965 158031 0 None - 1 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAntagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 468 4 1 4 3.7 O=C(Nc1cc(F)c(F)c(F)c1)c1cc(S(=O)(=O)N2CCOCC2)c(Cl)cc1Cl 10.1021/acs.jmedchem.6b01270
66774778 145799 0 None - 1 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cc(C)ccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3917128 145799 0 None - 1 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cc(C)ccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
46213949 372 47 None 5 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 10.1021/jm301022v
6988 372 47 None 5 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 10.1021/jm301022v
CHEMBL2182052 372 47 None 5 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 10.1021/jm301022v
122191544 123677 0 None -5 4 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization by Fura-2 AM probe-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization by Fura-2 AM probe-based fluorometric analysis
ChEMBL 484 18 3 4 5.4 CCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)CC(Br)P(=O)(O)O 10.1039/C4MD00333K
CHEMBL3621964 123677 0 None -5 4 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization by Fura-2 AM probe-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in RH7777 cells assessed as inhibition of LPA-induced calcium mobilization by Fura-2 AM probe-based fluorometric analysis
ChEMBL 484 18 3 4 5.4 CCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)CC(Br)P(=O)(O)O 10.1039/C4MD00333K
10367662 2173 91 None -1 5 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/jm301022v
2907 2173 91 None -1 5 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/jm301022v
CHEMBL361501 2173 91 None -1 5 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/jm301022v
10367662 2173 91 None 1 5 Rat 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmcl.2007.04.024
2907 2173 91 None 1 5 Rat 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmcl.2007.04.024
CHEMBL361501 2173 91 None 1 5 Rat 6.8 pIC50 = 6.8 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmcl.2007.04.024
66775043 2914 34 None 53 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 461 11 1 4 4.9 COc1cc(cc(c1C)OC)C(=O)N(Cc1ccc(cc1)CC(=O)O)CCCc1ccccc1 10.1021/acsmedchemlett.6b00225
9499 2914 34 None 53 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 461 11 1 4 4.9 COc1cc(cc(c1C)OC)C(=O)N(Cc1ccc(cc1)CC(=O)O)CCCc1ccccc1 10.1021/acsmedchemlett.6b00225
CHEMBL3941037 2914 34 None 53 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 461 11 1 4 4.9 COc1cc(cc(c1C)OC)C(=O)N(Cc1ccc(cc1)CC(=O)O)CCCc1ccccc1 10.1021/acsmedchemlett.6b00225
66775043 2914 34 None 53 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 461 11 1 4 4.9 COc1cc(cc(c1C)OC)C(=O)N(Cc1ccc(cc1)CC(=O)O)CCCc1ccccc1 10.1021/acsmedchemlett.7b00383
9499 2914 34 None 53 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 461 11 1 4 4.9 COc1cc(cc(c1C)OC)C(=O)N(Cc1ccc(cc1)CC(=O)O)CCCc1ccccc1 10.1021/acsmedchemlett.7b00383
CHEMBL3941037 2914 34 None 53 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 461 11 1 4 4.9 COc1cc(cc(c1C)OC)C(=O)N(Cc1ccc(cc1)CC(=O)O)CCCc1ccccc1 10.1021/acsmedchemlett.7b00383
71457478 83089 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 460 7 2 6 5.1 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC(C)C1CCC1 10.1021/jm301022v
CHEMBL2182035 83089 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 460 7 2 6 5.1 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC(C)C1CCC1 10.1021/jm301022v
2905 388 49 None -1 7 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysis
ChEMBL 490 7 2 5 6.9 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C 10.1039/C4MD00333K
46240292 388 49 None -1 7 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysis
ChEMBL 490 7 2 5 6.9 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C 10.1039/C4MD00333K
CHEMBL3621966 388 49 None -1 7 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysis
ChEMBL 490 7 2 5 6.9 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C 10.1039/C4MD00333K
71457480 83099 0 None 2 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
CHEMBL2182046 83099 0 None 2 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
11305821 93657 0 None -3 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 464 9 2 6 6.1 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCCC1 10.1016/j.bmcl.2007.04.024
CHEMBL246943 93657 0 None -3 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 464 9 2 6 6.1 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCCC1 10.1016/j.bmcl.2007.04.024
23080067 143983 0 None - 1 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 463 9 1 2 6.6 Cc1cccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3902849 143983 0 None - 1 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 463 9 1 2 6.6 Cc1cccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
71455702 83086 0 None 39 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
CHEMBL2182032 83086 0 None 39 2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
71457483 83104 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 321 4 1 4 4.4 C[C@@H](OC(=O)Nc1c(-c2ccccc2)cnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182053 83104 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 321 4 1 4 4.4 C[C@@H](OC(=O)Nc1c(-c2ccccc2)cnn1C)c1ccccc1 10.1021/jm301022v
71459352 83081 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 431 6 2 5 5.0 Cn1ncc(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC1CCC1 10.1021/jm301022v
CHEMBL2182026 83081 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 431 6 2 5 5.0 Cn1ncc(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC1CCC1 10.1021/jm301022v
70856266 83096 0 None 120 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182043 83096 0 None 120 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
71455703 83097 0 None 1445 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 500 7 2 6 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2F)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182044 83097 0 None 1445 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 500 7 2 6 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2F)nnn1C)c1ccccc1 10.1021/jm301022v
70856266 83096 0 None 120 2 Human 7.8 pIC50 = 7.8 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1ccccc1 nan
CHEMBL2182043 83096 0 None 120 2 Human 7.8 pIC50 = 7.8 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1ccccc1 nan
71455703 83097 0 None 1445 2 Human 7.8 pIC50 = 7.8 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 500 7 2 6 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2F)nnn1C)c1ccccc1 nan
CHEMBL2182044 83097 0 None 1445 2 Human 7.8 pIC50 = 7.8 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 500 7 2 6 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2F)nnn1C)c1ccccc1 nan
71457480 83099 0 None 2 2 Human 7.8 pIC50 = 7.8 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 550 7 2 6 6.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
CHEMBL2182046 83099 0 None 2 2 Human 7.8 pIC50 = 7.8 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 550 7 2 6 6.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
71452129 83101 0 None 120 2 Human 7.7 pIC50 = 7.7 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 559 8 2 8 4.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1ccccc1 nan
CHEMBL2182049 83101 0 None 120 2 Human 7.7 pIC50 = 7.7 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 559 8 2 8 4.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1ccccc1 nan
66862638 163035 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 452 12 2 6 4.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2cnc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4176330 163035 0 None - 1 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 452 12 2 6 4.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2cnc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
132191134 155829 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAntagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 500 4 1 4 4.7 O=C(Nc1cc(Cl)c(F)c(Cl)c1)c1cc(S(=O)(=O)N2CCOCC2)c(Cl)cc1Cl 10.1021/acs.jmedchem.6b01270
CHEMBL4060128 155829 0 None - 1 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAntagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 500 4 1 4 4.7 O=C(Nc1cc(Cl)c(F)c(Cl)c1)c1cc(S(=O)(=O)N2CCOCC2)c(Cl)cc1Cl 10.1021/acs.jmedchem.6b01270
71452129 83101 0 None 120 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 559 8 2 8 4.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182049 83101 0 None 120 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 559 8 2 8 4.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
66774667 143847 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 11 1 4 5.1 COc1cc(C(=O)N(CCCc2cccc(F)c2)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3901754 143847 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 11 1 4 5.1 COc1cc(C(=O)N(CCCc2cccc(F)c2)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
70856266 83096 0 None 120 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182043 83096 0 None 120 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
71455703 83097 0 None 1445 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 500 7 2 6 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2F)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182044 83097 0 None 1445 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 500 7 2 6 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2F)nnn1C)c1ccccc1 10.1021/jm301022v
66553162 83110 1 None 407 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 481 7 2 5 6.2 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182063 83110 1 None 407 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 481 7 2 5 6.2 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccccc1 10.1021/jm301022v
44441093 93555 0 None -2 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 442 9 2 5 6.1 CC(OC(=O)Nc1conc1-c1ccc(CCCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246527 93555 0 None -2 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 442 9 2 5 6.1 CC(OC(=O)Nc1conc1-c1ccc(CCCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
66553162 83110 1 None 407 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 481 7 2 5 6.2 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182063 83110 1 None 407 2 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 481 7 2 5 6.2 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccccc1 10.1021/jm301022v
66773977 151089 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 523 12 1 4 6.3 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3CC(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3959223 151089 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 523 12 1 4 6.3 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3CC(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
71462861 83087 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 448 7 2 6 5.0 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)C(C)C 10.1021/jm301022v
CHEMBL2182033 83087 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 448 7 2 6 5.0 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)C(C)C 10.1021/jm301022v
118067342 160407 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 399 5 0 5 4.1 C[C@@H](OC(=O)Cc1c(-c2ccc(Br)cc2)nnn1C)c1ccccc1 nan
CHEMBL4111515 160407 0 None - 1 Human 4.7 pIC50 = 4.7 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 399 5 0 5 4.1 C[C@@H](OC(=O)Cc1c(-c2ccc(Br)cc2)nnn1C)c1ccccc1 nan
66861759 162176 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 465 13 2 5 5.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4162680 162176 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 465 13 2 5 5.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
71457482 83103 0 None 165 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 462 7 2 6 5.5 C[C@@H](OC(=O)Nc1c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182051 83103 0 None 165 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 462 7 2 6 5.5 C[C@@H](OC(=O)Nc1c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
744590 191212 27 None -10 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 304 6 4 4 0.8 O=C(O)/C=C/C(=O)Nc1cccc(NC(=O)/C=C/C(=O)O)c1 10.1016/j.bmc.2008.04.035
CHEMBL519002 191212 27 None -10 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 304 6 4 4 0.8 O=C(O)/C=C/C(=O)Nc1cccc(NC(=O)/C=C/C(=O)O)c1 10.1016/j.bmc.2008.04.035
744590 191212 27 None -10 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 304 6 4 4 0.8 O=C(O)/C=C/C(=O)Nc1cccc(NC(=O)/C=C/C(=O)O)c1 10.1016/j.bmc.2009.09.022
CHEMBL519002 191212 27 None -10 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 304 6 4 4 0.8 O=C(O)/C=C/C(=O)Nc1cccc(NC(=O)/C=C/C(=O)O)c1 10.1016/j.bmc.2009.09.022
66774701 149225 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 11 1 4 5.1 COc1cc(C(=O)N(CCCc2ccccc2F)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3944344 149225 0 None - 1 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 11 1 4 5.1 COc1cc(C(=O)N(CCCc2ccccc2F)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
11374611 93648 0 None -4 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246929 93648 0 None -4 2 Human 6.7 pIC50 = 6.7 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
11312382 67327 1 None -21 3 Human 5.7 pIC50 = 5.7 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 292 13 2 2 4.6 CC/C=C/CCCCCCCCCCOP(=O)(O)O 10.1021/jm049609r
CHEMBL188591 67327 1 None -21 3 Human 5.7 pIC50 = 5.7 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 292 13 2 2 4.6 CC/C=C/CCCCCCCCCCOP(=O)(O)O 10.1021/jm049609r
155153661 172395 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 498 8 2 6 5.8 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cc2)c1CNC(=O)OCc1ccc(Cl)cc1 10.1021/acsmedchemlett.9b00429
CHEMBL4476814 172395 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 498 8 2 6 5.8 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cc2)c1CNC(=O)OCc1ccc(Cl)cc1 10.1021/acsmedchemlett.9b00429
71462862 83092 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 506 7 2 8 5.1 Cc1nnn(-c2ccc(-c3ccc(C4(c5nnn[nH]5)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
CHEMBL2182038 83092 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 506 7 2 8 5.1 Cc1nnn(-c2ccc(-c3ccc(C4(c5nnn[nH]5)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
11271067 162675 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 457 12 2 6 4.9 COc1cc([C@@H](O)[C@@H](CCCc2ccsc2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4170604 162675 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 457 12 2 6 4.9 COc1cc([C@@H](O)[C@@H](CCCc2ccsc2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
66774424 143159 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 537 13 1 4 6.7 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3CCC(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3896148 143159 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 537 13 1 4 6.7 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3CCC(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
82327 67129 14 None -5 2 Human 5.6 pIC50 = 5.6 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 294 14 2 2 4.8 CCCCCCCCCCCCCCOP(=O)(O)O 10.1021/jm049609r
CHEMBL187633 67129 14 None -5 2 Human 5.6 pIC50 = 5.6 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 294 14 2 2 4.8 CCCCCCCCCCCCCCOP(=O)(O)O 10.1021/jm049609r
71457481 83102 0 None 2 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 627 8 2 8 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
CHEMBL2182050 83102 0 None 2 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 627 8 2 8 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
71452130 83111 0 None 239 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 499 7 2 5 6.3 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccccc1F 10.1021/jm301022v
CHEMBL2182064 83111 0 None 239 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 499 7 2 5 6.3 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccccc1F 10.1021/jm301022v
71457481 83102 0 None 2 2 Human 7.6 pIC50 = 7.6 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 627 8 2 8 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
CHEMBL2182050 83102 0 None 2 2 Human 7.6 pIC50 = 7.6 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 627 8 2 8 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
10282223 3979 4 None -7 3 Human 5.6 pIC50 = 5.6 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](Cc1ccc(cc1)OCc1ccccc1)COP(=O)(O)O 10.1016/j.bmcl.2004.03.076
2909 3979 4 None -7 3 Human 5.6 pIC50 = 5.6 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](Cc1ccc(cc1)OCc1ccccc1)COP(=O)(O)O 10.1016/j.bmcl.2004.03.076
CHEMBL327240 3979 4 None -7 3 Human 5.6 pIC50 = 5.6 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](Cc1ccc(cc1)OCc1ccccc1)COP(=O)(O)O 10.1016/j.bmcl.2004.03.076
46213949 372 47 None 5 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysis
ChEMBL 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 10.1039/C4MD00333K
6988 372 47 None 5 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysis
ChEMBL 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 10.1039/C4MD00333K
CHEMBL2182052 372 47 None 5 2 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysisAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated for 30 mins followed by LPA induction by FLIPR Calcium 4 dye-based fluorometric analysis
ChEMBL 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 10.1039/C4MD00333K
71265339 83082 22 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 482 7 2 6 5.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
CHEMBL2182029 83082 22 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 482 7 2 6 5.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
11393306 67385 1 None -1 2 Human 5.6 pIC50 = 5.6 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 328 14 2 1 5.8 CCCCCCCCCCCCCCC(F)(F)P(=O)(O)O 10.1021/jm049609r
CHEMBL188859 67385 1 None -1 2 Human 5.6 pIC50 = 5.6 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 328 14 2 1 5.8 CCCCCCCCCCCCCCC(F)(F)P(=O)(O)O 10.1021/jm049609r
66773650 142427 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 477 9 1 2 6.9 Cc1cc(C)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3890162 142427 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 477 9 1 2 6.9 Cc1cc(C)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
66773644 147534 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 509 11 1 4 6.3 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL3930834 147534 0 None - 1 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 509 11 1 4 6.3 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
44441080 93647 0 None -3 2 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1cnoc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246928 93647 0 None -3 2 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1cnoc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
71455704 83100 0 None 2 2 Human 5.6 pIC50 = 5.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.6 C[C@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
CHEMBL2182047 83100 0 None 2 2 Human 5.6 pIC50 = 5.6 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 550 7 2 6 6.6 C[C@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
71455704 83100 0 None 2 2 Human 5.6 pIC50 = 5.6 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 550 7 2 6 6.6 C[C@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
CHEMBL2182047 83100 0 None 2 2 Human 5.6 pIC50 = 5.6 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 550 7 2 6 6.6 C[C@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
150134920 170445 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 501 8 2 7 4.8 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNC(=O)OCc1cc(F)cc(F)c1 10.1021/acsmedchemlett.9b00429
CHEMBL4448922 170445 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 501 8 2 7 4.8 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNC(=O)OCc1cc(F)cc(F)c1 10.1021/acsmedchemlett.9b00429
2260227 184063 10 None -3090 3 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 488 10 4 6 4.4 O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1 10.1016/j.bmc.2008.04.035
CHEMBL482498 184063 10 None -3090 3 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 488 10 4 6 4.4 O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1 10.1016/j.bmc.2008.04.035
2260227 184063 10 None -3090 3 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 488 10 4 6 4.4 O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1 10.1016/j.bmc.2009.09.022
CHEMBL482498 184063 10 None -3090 3 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 488 10 4 6 4.4 O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1 10.1016/j.bmc.2009.09.022
11409276 148720 0 None -2 2 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 492 9 2 7 4.7 CC(OC(=O)Nc1conc1-c1ccc(CS(=O)(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL394038 148720 0 None -2 2 Human 6.6 pIC50 = 6.6 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 492 9 2 7 4.7 CC(OC(=O)Nc1conc1-c1ccc(CS(=O)(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
75816 67143 53 None -7 3 Human 5.6 pIC50 = 5.6 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 266 12 2 2 4.0 CCCCCCCCCCCCOP(=O)(O)O 10.1021/jm049609r
CHEMBL187711 67143 53 None -7 3 Human 5.6 pIC50 = 5.6 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 266 12 2 2 4.0 CCCCCCCCCCCCOP(=O)(O)O 10.1021/jm049609r
11316893 93845 0 None 4 2 Rat 7.5 pIC50 = 7.5 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 450 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCC1 10.1016/j.bmcl.2007.04.024
CHEMBL247959 93845 0 None 4 2 Rat 7.5 pIC50 = 7.5 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 450 9 2 6 5.7 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCC1 10.1016/j.bmcl.2007.04.024
66862202 162260 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 457 12 2 6 4.9 COc1cc([C@@H](O)[C@@H](CCCc2cccs2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4164105 162260 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 457 12 2 6 4.9 COc1cc([C@@H](O)[C@@H](CCCc2cccs2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
44325401 106091 0 None -1 2 Human 5.5 pIC50 = 5.5 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 627 23 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OC2Cc3ccccc3C2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL313413 106091 0 None -1 2 Human 5.5 pIC50 = 5.5 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 627 23 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OC2Cc3ccccc3C2)cc1 10.1016/j.bmcl.2004.03.076
73335985 113979 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 385 3 1 6 3.2 N#Cc1cnn(/C(=N/C2CCCC2)C(=O)c2ccc(Br)cc2)c1N 10.1016/j.bmcl.2014.08.001
CHEMBL3326525 113979 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 385 3 1 6 3.2 N#Cc1cnn(/C(=N/C2CCCC2)C(=O)c2ccc(Br)cc2)c1N 10.1016/j.bmcl.2014.08.001
66774777 153027 0 None 229 2 Human 8.5 pIC50 = 8.5 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 573 12 1 5 7.4 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccc(Cl)cc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3975893 153027 0 None 229 2 Human 8.5 pIC50 = 8.5 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 573 12 1 5 7.4 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccc(Cl)cc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
66862629 162369 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 452 12 2 6 4.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2cc(CC(=O)O)cn2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4165714 162369 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 452 12 2 6 4.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2cc(CC(=O)O)cn2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
11197104 67596 1 None -31 3 Human 5.5 pIC50 = 5.5 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 292 13 2 2 4.6 CCCC/C=C/CCCCCCCCOP(=O)(O)O 10.1021/jm049609r
CHEMBL190430 67596 1 None -31 3 Human 5.5 pIC50 = 5.5 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 292 13 2 2 4.6 CCCC/C=C/CCCCCCCCOP(=O)(O)O 10.1021/jm049609r
71450322 83091 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 559 8 2 8 4.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
CHEMBL2182037 83091 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 559 8 2 8 4.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)NS(C)(=O)=O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
66862841 162580 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 452 12 2 6 4.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CC(=O)O)n2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4169137 162580 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 452 12 2 6 4.2 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CC(=O)O)n2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
66774229 145244 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 10 1 3 6.3 COc1ccccc1C(=O)N(CCCc1ccccc1)Cc1ccc(-c2ccccc2C(=O)O)cc1 10.1021/acsmedchemlett.6b00225
CHEMBL3912909 145244 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 10 1 3 6.3 COc1ccccc1C(=O)N(CCCc1ccccc1)Cc1ccc(-c2ccccc2C(=O)O)cc1 10.1021/acsmedchemlett.6b00225
73336083 113981 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 397 6 1 9 2.4 COc1cc(OC)c(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)cc1OC 10.1016/j.bmcl.2014.08.001
CHEMBL3326529 113981 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 397 6 1 9 2.4 COc1cc(OC)c(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)cc1OC 10.1016/j.bmcl.2014.08.001
66861497 162826 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 466 13 2 6 4.6 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2cc(CCC(=O)O)cn2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4172946 162826 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 466 13 2 6 4.6 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2cc(CCC(=O)O)cn2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
71461120 83084 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 500 7 2 6 5.8 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1F 10.1021/jm301022v
CHEMBL2182030 83084 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 500 7 2 6 5.8 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1F 10.1021/jm301022v
71457480 83099 0 None 2 2 Human 6.5 pIC50 = 6.5 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 550 7 2 6 6.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
CHEMBL2182046 83099 0 None 2 2 Human 6.5 pIC50 = 6.5 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 550 7 2 6 6.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
70819507 83109 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 455 7 2 5 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)cnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182061 83109 0 None - 1 Human 7.5 pIC50 = 7.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 455 7 2 5 5.7 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)cnn1C)c1ccccc1 10.1021/jm301022v
70819486 83105 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 355 4 1 4 5.1 CC(OC(=O)Nc1c(-c2ccccc2)cnn1C)c1ccccc1Cl 10.1021/jm301022v
CHEMBL2182056 83105 0 None - 1 Human 5.5 pIC50 = 5.5 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 355 4 1 4 5.1 CC(OC(=O)Nc1c(-c2ccccc2)cnn1C)c1ccccc1Cl 10.1021/jm301022v
71267051 83094 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 468 7 2 6 5.4 C[C@@H](OC(=O)Nc1cnnn1-c1ccc(-c2ccc(C3(C(=O)O)CC3)cc2)cc1)c1ccccc1 10.1021/jm301022v
CHEMBL2182040 83094 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 468 7 2 6 5.4 C[C@@H](OC(=O)Nc1cnnn1-c1ccc(-c2ccc(C3(C(=O)O)CC3)cc2)cc1)c1ccccc1 10.1021/jm301022v
44441096 93606 0 None -3 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 470 9 2 5 6.7 CC(OC(=O)Nc1conc1-c1ccc(CCC(C)(C)CC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246734 93606 0 None -3 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 470 9 2 5 6.7 CC(OC(=O)Nc1conc1-c1ccc(CCC(C)(C)CC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
66774362 153443 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 509 11 1 4 6.3 COc1ccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)cc1OC 10.1021/acsmedchemlett.6b00225
CHEMBL3979511 153443 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 509 11 1 4 6.3 COc1ccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)cc1OC 10.1021/acsmedchemlett.6b00225
71462859 83079 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 433 7 2 5 5.2 CC[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C 10.1021/jm301022v
CHEMBL2182024 83079 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 433 7 2 5 5.2 CC[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C 10.1021/jm301022v
66861902 162756 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 471 13 2 6 5.3 COc1cc([C@@H](O)[C@@H](CCCc2ccsc2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4171981 162756 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 471 13 2 6 5.3 COc1cc([C@@H](O)[C@@H](CCCc2ccsc2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
71453960 83095 0 None 162 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 456 7 2 6 5.1 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182042 83095 0 None 162 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assayAntagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay
ChEMBL 456 7 2 6 5.1 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
23079111 150012 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 539 12 1 5 6.4 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)cc(OC)c1OC 10.1021/acsmedchemlett.6b00225
CHEMBL3950523 150012 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 539 12 1 5 6.4 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)cc(OC)c1OC 10.1021/acsmedchemlett.6b00225
71461124 83106 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 373 4 1 4 5.2 CC(OC(=O)Nc1c(-c2ccc(F)cc2)cnn1C)c1ccccc1Cl 10.1021/jm301022v
CHEMBL2182057 83106 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 373 4 1 4 5.2 CC(OC(=O)Nc1c(-c2ccc(F)cc2)cnn1C)c1ccccc1Cl 10.1021/jm301022v
71450321 83088 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 434 7 2 6 4.7 CC[C@@H](C)OC(=O)Nc1c(C)nnn1-c1ccc(-c2ccc(C3(C(=O)O)CC3)cc2)cc1 10.1021/jm301022v
CHEMBL2182034 83088 0 None - 1 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 434 7 2 6 4.7 CC[C@@H](C)OC(=O)Nc1c(C)nnn1-c1ccc(-c2ccc(C3(C(=O)O)CC3)cc2)cc1 10.1021/jm301022v
142610742 170010 0 None - 1 Human 8.4 pIC50 = 8.4 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 499 10 2 7 3.7 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNS(=O)(=O)CCc1ccccc1 10.1021/acsmedchemlett.9b00429
CHEMBL4442789 170010 0 None - 1 Human 8.4 pIC50 = 8.4 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 499 10 2 7 3.7 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNS(=O)(=O)CCc1ccccc1 10.1021/acsmedchemlett.9b00429
66861761 162142 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 466 13 2 6 4.6 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CCC(=O)O)n2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4162273 162142 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 466 13 2 6 4.6 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2ccc(CCC(=O)O)n2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
71462858 83078 0 None 11 2 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 549 7 2 5 7.2 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
CHEMBL2182023 83078 0 None 11 2 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 549 7 2 5 7.2 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1cccc(C(F)(F)F)c1 10.1021/jm301022v
134148024 149657 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccc(C)cc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3947597 149657 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 553 12 1 5 7.1 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccc(C)cc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
71459353 83093 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 496 8 2 6 5.9 CCc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
CHEMBL2182039 83093 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 496 8 2 6 5.9 CCc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1 10.1021/jm301022v
44325312 206927 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 599 23 3 4 8.2 CCCCC/C=C\C/C=C\CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL91168 206927 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 599 23 3 4 8.2 CCCCC/C=C\C/C=C\CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
11340921 93298 0 None -5 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 496 9 2 7 5.4 CC(OC(=O)Nc1conc1-c1ccc(CSCCS(=O)(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL245295 93298 0 None -5 2 Human 6.4 pIC50 = 6.4 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 496 9 2 7 5.4 CC(OC(=O)Nc1conc1-c1ccc(CSCCS(=O)(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
66775156 144122 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 10 1 3 6.3 COc1ccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)cc1 10.1021/acsmedchemlett.6b00225
CHEMBL3903904 144122 0 None - 1 Human 5.4 pIC50 = 5.4 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 479 10 1 3 6.3 COc1ccc(C(=O)N(CCCc2ccccc2)Cc2ccc(-c3ccccc3C(=O)O)cc2)cc1 10.1021/acsmedchemlett.6b00225
72704618 159891 0 None 4 2 Human 5.4 pIC50 = 5.4 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3cccc(C4(C(=O)O)CC4)c3)cc2)nnn1C)c1ccccc1 nan
CHEMBL4107074 159891 0 None 4 2 Human 5.4 pIC50 = 5.4 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 482 7 2 6 5.6 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3cccc(C4(C(=O)O)CC4)c3)cc2)nnn1C)c1ccccc1 nan
66862949 162973 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 471 13 2 6 5.3 COc1cc([C@@H](O)[C@@H](CCCc2cccs2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4175424 162973 0 None - 1 Human 7.4 pIC50 = 7.4 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 471 13 2 6 5.3 COc1cc([C@@H](O)[C@@H](CCCc2cccs2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
10367662 2173 91 None -1 5 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assayAntagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmc.2009.12.020
2907 2173 91 None -1 5 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assayAntagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmc.2009.12.020
CHEMBL361501 2173 91 None -1 5 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assayAntagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmc.2009.12.020
72704617 152227 0 None 6 2 Human 7.3 pIC50 = 7.3 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 550 7 2 6 6.6 CC(OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
CHEMBL3969018 152227 0 None 6 2 Human 7.3 pIC50 = 7.3 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 550 7 2 6 6.6 CC(OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C)c1cccc(C(F)(F)F)c1 nan
66775340 162476 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 460 12 1 4 5.7 COc1cc(C(=O)C(CCCc2ccccc2)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4167471 162476 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 460 12 1 4 5.7 COc1cc(C(=O)C(CCCc2ccccc2)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
11374611 93648 0 None 4 2 Rat 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246929 93648 0 None 4 2 Rat 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
71453960 83095 0 None 162 2 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 456 7 2 6 5.1 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182042 83095 0 None 162 2 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 456 7 2 6 5.1 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
71453960 83095 0 None 162 2 Human 7.3 pIC50 = 7.3 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 456 7 2 6 5.1 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)nnn1C)c1ccccc1 nan
CHEMBL2182042 83095 0 None 162 2 Human 7.3 pIC50 = 7.3 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 456 7 2 6 5.1 C[C@@H](OC(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)nnn1C)c1ccccc1 nan
155153676 174586 0 None - 1 Human 8.3 pIC50 = 8.3 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 483 8 2 7 4.6 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNC(=O)OCc1cccc(F)c1 10.1021/acsmedchemlett.9b00429
CHEMBL4557434 174586 0 None - 1 Human 8.3 pIC50 = 8.3 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 483 8 2 7 4.6 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNC(=O)OCc1cccc(F)c1 10.1021/acsmedchemlett.9b00429
66775301 153147 0 None - 1 Human 8.2 pIC50 = 8.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 573 12 1 5 7.4 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cc(Cl)ccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3976876 153147 0 None - 1 Human 8.2 pIC50 = 8.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 573 12 1 5 7.4 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3cc(Cl)ccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
44454369 155590 0 None 239 2 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 expressed in RH7777 cells with Gi4-protein and aequorin by calcium mobilization assayAntagonist activity at LPA1 expressed in RH7777 cells with Gi4-protein and aequorin by calcium mobilization assay
ChEMBL 322 4 1 4 5.0 Cc1noc(-c2ccccc2)c1NC(=O)OC(C)c1ccccc1 10.1016/j.bmcl.2007.12.024
CHEMBL404575 155590 0 None 239 2 Human 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 expressed in RH7777 cells with Gi4-protein and aequorin by calcium mobilization assayAntagonist activity at LPA1 expressed in RH7777 cells with Gi4-protein and aequorin by calcium mobilization assay
ChEMBL 322 4 1 4 5.0 Cc1noc(-c2ccccc2)c1NC(=O)OC(C)c1ccccc1 10.1016/j.bmcl.2007.12.024
73336085 113984 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 381 5 1 8 2.8 COc1ccc(C(=O)/C(=N\C2CCCCC2)n2ncc(C#N)c2N)c(OC)c1 10.1016/j.bmcl.2014.08.001
CHEMBL3326533 113984 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 381 5 1 8 2.8 COc1ccc(C(=O)/C(=N\C2CCCCC2)n2ncc(C#N)c2N)c(OC)c1 10.1016/j.bmcl.2014.08.001
10367662 2173 91 None -1 5 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmcl.2007.04.024
2907 2173 91 None -1 5 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmcl.2007.04.024
CHEMBL361501 2173 91 None -1 5 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1016/j.bmcl.2007.04.024
66862428 162084 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 480 12 2 6 4.8 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2nc(C)c(CC(=O)O)c2C)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4161219 162084 0 None - 1 Human 6.3 pIC50 = 6.3 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 480 12 2 6 4.8 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cn2nc(C)c(CC(=O)O)c2C)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
5311306 96518 2 None 1 2 Human 5.3 pIC50 = 5.3 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL262906 96518 2 None 1 2 Human 5.3 pIC50 = 5.3 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
66774976 146401 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 467 9 1 2 6.5 O=C(O)c1ccccc1-c1ccc(CN(CCCc2ccccc2)C(=O)c2cccc(F)c2)cc1 10.1021/acsmedchemlett.6b00225
CHEMBL3921894 146401 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 467 9 1 2 6.5 O=C(O)c1ccccc1-c1ccc(CN(CCCc2ccccc2)C(=O)c2cccc(F)c2)cc1 10.1021/acsmedchemlett.6b00225
10051843 1417 2 None -24 2 Human 5.3 pIC50 = 5.3 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 504 20 3 8 4.4 CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC)COP(=O)(OP(=O)(O)O)O 10.1021/jm049609r
2916 1417 2 None -24 2 Human 5.3 pIC50 = 5.3 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 504 20 3 8 4.4 CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC)COP(=O)(OP(=O)(O)O)O 10.1021/jm049609r
CHEMBL191055 1417 2 None -24 2 Human 5.3 pIC50 = 5.3 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 504 20 3 8 4.4 CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC)COP(=O)(OP(=O)(O)O)O 10.1021/jm049609r
11305821 93657 0 None 3 2 Rat 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 464 9 2 6 6.1 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCCC1 10.1016/j.bmcl.2007.04.024
CHEMBL246943 93657 0 None 3 2 Rat 7.3 pIC50 = 7.3 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 464 9 2 6 6.1 CC(OC(=O)Nc1conc1-c1ccc(CSCCC(=O)O)cc1)C1=C(Cl)CCCC1 10.1016/j.bmcl.2007.04.024
11599847 206713 0 None -8 2 Human 5.3 pIC50 = 5.3 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL89937 206713 0 None -8 2 Human 5.3 pIC50 = 5.3 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
71452131 83112 0 None 144 2 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 499 7 2 5 6.3 CC(OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccc(F)cc1 10.1021/jm301022v
CHEMBL2182065 83112 0 None 144 2 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 499 7 2 5 6.3 CC(OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)cnn1C)c1ccc(F)cc1 10.1021/jm301022v
71457482 83103 0 None 165 2 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 462 7 2 6 5.5 C[C@@H](OC(=O)Nc1c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
CHEMBL2182051 83103 0 None 165 2 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 462 7 2 6 5.5 C[C@@H](OC(=O)Nc1c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nnn1C)c1ccccc1 10.1021/jm301022v
71457482 83103 0 None 165 2 Human 7.2 pIC50 = 7.2 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 462 7 2 6 5.5 C[C@@H](OC(=O)Nc1c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nnn1C)c1ccccc1 nan
CHEMBL2182051 83103 0 None 165 2 Human 7.2 pIC50 = 7.2 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 462 7 2 6 5.5 C[C@@H](OC(=O)Nc1c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nnn1C)c1ccccc1 nan
73335984 113978 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 335 4 1 6 3.0 CCc1ccc(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)cc1 10.1016/j.bmcl.2014.08.001
CHEMBL3326524 113978 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 335 4 1 6 3.0 CCc1ccc(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)cc1 10.1016/j.bmcl.2014.08.001
56943915 123679 6 None - 1 Human 8.2 pIC50 = 8.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated with protein followed by LPA induction measured for 2 mins by Fluo-4 dye-based FLIPR assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated with protein followed by LPA induction measured for 2 mins by Fluo-4 dye-based FLIPR assay
ChEMBL 549 11 2 8 3.0 COc1ccc([C@@H](O)C(=O)N(CCCc2ccccc2)Cc2nc(C(=O)NS(C)(=O)=O)c(C)s2)c(F)c1 10.1039/C4MD00333K
CHEMBL3621968 123679 6 None - 1 Human 8.2 pIC50 = 8.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated with protein followed by LPA induction measured for 2 mins by Fluo-4 dye-based FLIPR assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as inhibition of LPA-induced calcium mobilization preincubated with protein followed by LPA induction measured for 2 mins by Fluo-4 dye-based FLIPR assay
ChEMBL 549 11 2 8 3.0 COc1ccc([C@@H](O)C(=O)N(CCCc2ccccc2)Cc2nc(C(=O)NS(C)(=O)=O)c(C)s2)c(F)c1 10.1039/C4MD00333K
132191124 157691 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAntagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 484 4 1 4 4.2 O=C(Nc1cc(F)c(Cl)c(F)c1)c1cc(S(=O)(=O)N2CCOCC2)c(Cl)cc1Cl 10.1021/acs.jmedchem.6b01270
CHEMBL4082022 157691 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assayAntagonist activity at LPA1 receptor (unknown origin) expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium level measured every 3.42 secs for 70 secs by Fura-2-AM dye based fluorescence assay
ChEMBL 484 4 1 4 4.2 O=C(Nc1cc(F)c(Cl)c(F)c1)c1cc(S(=O)(=O)N2CCOCC2)c(Cl)cc1Cl 10.1021/acs.jmedchem.6b01270
44325682 106869 3 None 1 2 Human 6.2 pIC50 = 6.2 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL314555 106869 3 None 1 2 Human 6.2 pIC50 = 6.2 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
753410 201933 10 None 4 2 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 311 4 1 4 2.5 Cc1ccc(Oc2ccc3c(c2)C(=O)N(CC(=O)O)C3=O)cc1 10.1016/j.bmc.2009.09.022
CHEMBL607806 201933 10 None 4 2 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 311 4 1 4 2.5 Cc1ccc(Oc2ccc3c(c2)C(=O)N(CC(=O)O)C3=O)cc1 10.1016/j.bmc.2009.09.022
58902982 161986 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 462 12 2 4 5.6 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4159560 161986 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 462 12 2 4 5.6 COc1cc([C@@H](O)[C@@H](CCCc2ccccc2)Cc2ccc(CC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
11351723 162485 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 463 10 2 5 4.6 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4167552 162485 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 463 10 2 5 4.6 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
150336102 172050 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 499 9 2 7 4.0 Cc1nc(-c2onc(C)c2CNS(=O)(=O)Cc2ccccc2)ccc1O[C@H]1CCC[C@H](C(=O)O)C1 10.1021/acsmedchemlett.9b00429
CHEMBL4472223 172050 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 499 9 2 7 4.0 Cc1nc(-c2onc(C)c2CNS(=O)(=O)Cc2ccccc2)ccc1O[C@H]1CCC[C@H](C(=O)O)C1 10.1021/acsmedchemlett.9b00429
71462863 83107 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 373 4 1 4 5.2 C[C@@H](OC(=O)Nc1c(-c2ccccc2F)cnn1C)c1ccccc1Cl 10.1021/jm301022v
CHEMBL2182058 83107 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 373 4 1 4 5.2 C[C@@H](OC(=O)Nc1c(-c2ccccc2F)cnn1C)c1ccccc1Cl 10.1021/jm301022v
66775150 150314 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 491 13 1 5 5.1 COc1cc(C(=O)N(CCCCc2ccccc2)Cc2ccc(OCC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3953068 150314 0 None - 1 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 491 13 1 5 5.1 COc1cc(C(=O)N(CCCCc2ccccc2)Cc2ccc(OCC(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
66773671 145261 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 491 13 1 5 5.3 COc1cc(C(=O)N(CCCOc2cccc(C(=O)O)c2)CCCc2ccccc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3913038 145261 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 491 13 1 5 5.3 COc1cc(C(=O)N(CCCOc2cccc(C(=O)O)c2)CCCc2ccccc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
71457479 83098 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 448 7 2 6 4.9 CC(C)[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C 10.1021/jm301022v
CHEMBL2182045 83098 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 448 7 2 6 4.9 CC(C)[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C 10.1021/jm301022v
71457479 83098 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 448 7 2 6 4.9 CC(C)[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C nan
CHEMBL2182045 83098 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.Calcium Flux Assay Using Fluorometric Imaging Plate Reader (FLIPR) Assay: Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilutions, 10 mM stocks of compounds were prepared in 100% DMSO. The compound dilution plate was set up as follows: well #1 received 29 μL of stock compound and 31 μL DMSO. Wells 2-10 received 40 μL of DMSO. After mixing, 20 μL of solution from well #1 was transferred into well #2, followed by 1:3 serial dilutions out 10 steps. 2 μL of diluted compound was transferred into duplicate wells of 384 well "assay plate" and then 90 μL of buffer was added. After incubation, both the cell and "assay" plates were brought to the FLIPR and 20 μL of the diluted compounds were transferred to the cell plates by the FLIPR. Compound addition was monitored by the FLIPR to detect any agonist activity of the compounds. Plates were then incubated for 30 minutes at room temperature protected from light. After the incubation, plates were returned to the FLIPR and 20 μL of 4.5× concentrated agonist was added to the cell plates. During the assay, fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20 μL of sample was rapidly (30 μL/sec) and simultaneously added to each well of the cell plate. The fluorescence was continuously monitored before, during and after sample addition for a total elapsed time of 100 seconds.
ChEMBL 448 7 2 6 4.9 CC(C)[C@@H](C)OC(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)nnn1C nan
44325681 106868 0 None -2 2 Human 5.2 pIC50 = 5.2 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 626 23 4 4 9.1 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(Oc2cc3ccccc3[nH]2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL314554 106868 0 None -2 2 Human 5.2 pIC50 = 5.2 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 626 23 4 4 9.1 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(Oc2cc3ccccc3[nH]2)cc1 10.1016/j.bmcl.2004.03.076
66774888 152511 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 539 12 1 5 6.8 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
CHEMBL3971582 152511 0 None - 1 Human 7.2 pIC50 = 7.2 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 539 12 1 5 6.8 COc1cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccccc3C(=O)O)cc2)cc(OC)c1C 10.1021/acsmedchemlett.6b00225
44441093 93555 0 None 2 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 442 9 2 5 6.1 CC(OC(=O)Nc1conc1-c1ccc(CCCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246527 93555 0 None 2 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 442 9 2 5 6.1 CC(OC(=O)Nc1conc1-c1ccc(CCCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
11167018 93607 0 None 1 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 457 8 3 6 5.1 CC(OC(=O)Nc1conc1-c1ccc(NC(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246735 93607 0 None 1 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 457 8 3 6 5.1 CC(OC(=O)Nc1conc1-c1ccc(NC(=O)CCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
11340921 93298 0 None 5 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 496 9 2 7 5.4 CC(OC(=O)Nc1conc1-c1ccc(CSCCS(=O)(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL245295 93298 0 None 5 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 496 9 2 7 5.4 CC(OC(=O)Nc1conc1-c1ccc(CSCCS(=O)(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
73336082 113980 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 355 4 1 7 2.6 COc1ccc(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)c(F)c1 10.1016/j.bmcl.2014.08.001
CHEMBL3326527 113980 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 355 4 1 7 2.6 COc1ccc(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)c(F)c1 10.1016/j.bmcl.2014.08.001
10367662 2173 91 None -1 5 Human 6.1 pIC50 = 6.1 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/jm049609r
2907 2173 91 None -1 5 Human 6.1 pIC50 = 6.1 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/jm049609r
CHEMBL361501 2173 91 None -1 5 Human 6.1 pIC50 = 6.1 Functional
Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptorInhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/jm049609r
73332314 113977 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 367 5 1 8 2.4 COc1ccc(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)c(OC)c1 10.1016/j.bmcl.2014.08.001
CHEMBL3326523 113977 0 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 367 5 1 8 2.4 COc1ccc(C(=O)/C(=N\C2CCCC2)n2ncc(C#N)c2N)c(OC)c1 10.1016/j.bmcl.2014.08.001
44325214 207154 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 463 15 3 4 4.8 CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL92452 207154 0 None - 1 Human 5.1 pIC50 = 5.1 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 463 15 3 4 4.8 CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
11849496 79577 0 None 2 2 Human 6.1 pIC50 = 6.1 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 406 16 1 4 6.1 CCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
CHEMBL211465 79577 0 None 2 2 Human 6.1 pIC50 = 6.1 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 406 16 1 4 6.1 CCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
10367662 2173 91 None -1 5 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assayAntagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/acs.jmedchem.2c00046
2907 2173 91 None -1 5 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assayAntagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/acs.jmedchem.2c00046
CHEMBL361501 2173 91 None -1 5 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assayAntagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assay
ChEMBL 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 10.1021/acs.jmedchem.2c00046
73336084 113982 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 387 4 1 7 3.6 COc1cc2ccccc2cc1C(=O)/C(=N\C1CCCC1)n1ncc(C#N)c1N 10.1016/j.bmcl.2014.08.001
CHEMBL3326531 113982 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 387 4 1 7 3.6 COc1cc2ccccc2cc1C(=O)/C(=N\C1CCCC1)n1ncc(C#N)c1N 10.1016/j.bmcl.2014.08.001
44441080 93647 0 None 3 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1cnoc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
CHEMBL246928 93647 0 None 3 2 Rat 7.1 pIC50 = 7.1 Functional
Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influxAntagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx
ChEMBL 460 9 2 6 6.0 CC(OC(=O)Nc1cnoc1-c1ccc(CSCCC(=O)O)cc1)c1ccccc1Cl 10.1016/j.bmcl.2007.04.024
73335987 113983 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 377 4 1 7 2.9 COc1cc2c(cc1C(=O)/C(=N\C1CCCC1)n1ncc(C#N)c1N)CCC2 10.1016/j.bmcl.2014.08.001
CHEMBL3326532 113983 0 None - 1 Human 6.1 pIC50 = 6.1 Functional
Antagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assayAntagonist activity at human LPA1R expressed in Chem-1 cells assessed as inhibition of lysophosphatidic acid-induced calcium mobilization by FLIPR assay
ChEMBL 377 4 1 7 2.9 COc1cc2c(cc1C(=O)/C(=N\C1CCCC1)n1ncc(C#N)c1N)CCC2 10.1016/j.bmcl.2014.08.001
11317548 162346 11 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4165205 162346 11 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
CHEMBL4175820 162346 11 None - 1 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assayAntagonist activity at recombinant human LPA1 expressed in CHO cells assessed as reduction in LPA-induced intracellular calcium level pretreated followed by LPA addition by Fura-2-AM dye based fluorescence assay
ChEMBL 477 11 2 5 5.0 COc1cc([C@@H](O)[C@@H](CC2Cc3ccccc3C2)Cn2ccc(CCC(=O)O)c2)cc(OC)c1C 10.1021/acsmedchemlett.7b00383
9958483 97809 0 None -2 2 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 525 12 1 5 6.5 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
CHEMBL272087 97809 0 None -2 2 Human 7.1 pIC50 = 7.1 Functional
Antagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assayAntagonist activity at human LPA1 receptor expressed in CHO cells assessed as reduction in LPA-induced intracellular Ca2+ concentration pretreated with compound followed by LPA addition by fluorescence assay
ChEMBL 525 12 1 5 6.5 COc1cc(OC)cc(C(=O)N(CCCc2ccccc2)Cc2ccc(Oc3ccccc3C(=O)O)cc2)c1 10.1021/acsmedchemlett.6b00225
152069844 170012 0 None - 1 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 483 8 2 7 4.6 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNC(=O)OCc1ccc(F)cc1 10.1021/acsmedchemlett.9b00429
CHEMBL4442819 170012 0 None - 1 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 minsAntagonist activity at human LPA1 expressed in CHO cells assessed as reduction in LPA-induced calcium influx incubated for 20 mins
ChEMBL 483 8 2 7 4.6 Cc1noc(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)cn2)c1CNC(=O)OCc1ccc(F)cc1 10.1021/acsmedchemlett.9b00429
44325235 168083 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 547 21 3 4 7.1 CCCCCCCCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL432821 168083 0 None - 1 Human 5.0 pIC50 = 5.0 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 547 21 3 4 7.1 CCCCCCCCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
1365686 201385 36 None 5 3 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 404 5 1 6 3.9 O=C(O)c1ccc2c(c1)C(=O)N(c1cccc(Oc3ccc([N+](=O)[O-])cc3)c1)C2=O 10.1016/j.bmc.2009.09.022
CHEMBL604677 201385 36 None 5 3 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium responseAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium response
ChEMBL 404 5 1 6 3.9 O=C(O)c1ccc2c(c1)C(=O)N(c1cccc(Oc3ccc([N+](=O)[O-])cc3)c1)C2=O 10.1016/j.bmc.2009.09.022
16043259 79780 0 None 1 2 Human 6.0 pIC50 = 6.0 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 434 18 1 4 6.9 CCCCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
CHEMBL212029 79780 0 None 1 2 Human 6.0 pIC50 = 6.0 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 434 18 1 4 6.9 CCCCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
71461121 83090 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 434 5 2 6 4.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC(C)(C)C 10.1021/jm301022v
CHEMBL2182036 83090 0 None - 1 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assayAntagonist activity at human recombinant LPA1 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay
ChEMBL 434 5 2 6 4.7 Cc1nnn(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC(C)(C)C 10.1021/jm301022v
44325401 106091 0 None -1 2 Human 6.9 pKi = 6.9 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 627 23 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OC2Cc3ccccc3C2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL313413 106091 0 None -1 2 Human 6.9 pKi = 6.9 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 627 23 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OC2Cc3ccccc3C2)cc1 10.1016/j.bmcl.2004.03.076
2260227 184063 10 None -3090 3 Human 4.9 pKi = 4.9 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 488 10 4 6 4.4 O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1 10.1016/j.bmc.2008.04.035
CHEMBL482498 184063 10 None -3090 3 Human 4.9 pKi = 4.9 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 488 10 4 6 4.4 O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1 10.1016/j.bmc.2008.04.035
5311306 96518 2 None 1 2 Human 6.9 pKi = 6.9 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL262906 96518 2 None 1 2 Human 6.9 pKi = 6.9 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 601 24 3 4 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)NC(COP(=O)(O)O)Cc1ccc(OCc2ccccc2)cc1 10.1016/j.bmcl.2004.03.076
23725184 109240 1 None - 0 Human 6.8 pKi = 6.8 Functional
Competitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation countingCompetitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation counting
ChEMBL 670 24 3 5 8.8 CCCCCCCCCCCCCCCC(=O)N[C@@H](/C=C/P(=O)(O)O)Cc1ccc(OCc2cc(OCC(F)(F)F)ccn2)cc1 10.1039/c0md00273a
CHEMBL3218460 109240 1 None - 0 Human 6.8 pKi = 6.8 Functional
Competitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation countingCompetitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation counting
ChEMBL 670 24 3 5 8.8 CCCCCCCCCCCCCCCC(=O)N[C@@H](/C=C/P(=O)(O)O)Cc1ccc(OCc2cc(OCC(F)(F)F)ccn2)cc1 10.1039/c0md00273a
44325682 106869 3 None 1 2 Human 6.8 pKi = 6.8 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL314555 106869 3 None 1 2 Human 6.8 pKi = 6.8 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
16725999 728 1 None -9 2 Human 6.8 pKi = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assayAntagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assay
ChEMBL 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O 10.1039/C4MD00255E
6985 728 1 None -9 2 Human 6.8 pKi = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assayAntagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assay
ChEMBL 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O 10.1039/C4MD00255E
CHEMBL3621357 728 1 None -9 2 Human 6.8 pKi = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assayAntagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assay
ChEMBL 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O 10.1039/C4MD00255E
87470750 123791 0 None - 0 Human 6.8 pKi = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assayAntagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assay
ChEMBL 512 20 3 4 6.2 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)CC(Br)P(=O)(O)O 10.1039/C4MD00255E
CHEMBL3621353 123791 0 None - 0 Human 6.8 pKi = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assayAntagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assay
ChEMBL 512 20 3 4 6.2 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)CC(Br)P(=O)(O)O 10.1039/C4MD00255E
CHEMBL3623936 123791 0 None - 0 Human 6.8 pKi = 6.8 Functional
Antagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assayAntagonist activity at human LPA1 receptor expressed in RG7777 cells assessed as inhibition of LPA-induced Ca2+ mobilization by FURA-2AM dye based fluorescence assay
ChEMBL 512 20 3 4 6.2 CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)CC(Br)P(=O)(O)O 10.1039/C4MD00255E
10393842 169175 0 None 1 2 Human 7.8 pKi = 7.8 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL440696 169175 0 None 1 2 Human 7.8 pKi = 7.8 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 602 24 3 5 7.8 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2ccccn2)cc1 10.1016/j.bmcl.2004.03.076
11849496 79577 0 None 2 2 Human 6.5 pKi = 6.5 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 406 16 1 4 6.1 CCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
CHEMBL211465 79577 0 None 2 2 Human 6.5 pKi = 6.5 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 406 16 1 4 6.1 CCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
44325391 206906 0 None -30 2 Human 7.5 pKi = 7.5 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL91058 206906 0 None -30 2 Human 7.5 pKi = 7.5 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
11599847 206713 0 None -8 2 Human 6.5 pKi = 6.5 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL89937 206713 0 None -8 2 Human 6.5 pKi = 6.5 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 631 25 3 5 8.4 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](COP(=O)(O)O)Cc1ccc(OCc2cccc(OC)c2)cc1 10.1016/j.bmcl.2004.03.076
16043259 79780 0 None 1 2 Human 6.4 pKi = 6.4 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 434 18 1 4 6.9 CCCCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
CHEMBL212029 79780 0 None 1 2 Human 6.4 pKi = 6.4 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 434 18 1 4 6.9 CCCCCCCCCCCCCCCCCC(=O)OCC1CCP(O)(=S)O1 10.1021/jm060351+
744590 191212 27 None -10 2 Human 7.3 pKi = 7.3 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 304 6 4 4 0.8 O=C(O)/C=C/C(=O)Nc1cccc(NC(=O)/C=C/C(=O)O)c1 10.1016/j.bmc.2008.04.035
CHEMBL519002 191212 27 None -10 2 Human 7.3 pKi = 7.3 Functional
Antagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentrationAntagonist activity at LPA1 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration
ChEMBL 304 6 4 4 0.8 O=C(O)/C=C/C(=O)Nc1cccc(NC(=O)/C=C/C(=O)O)c1 10.1016/j.bmc.2008.04.035
44414925 78053 0 None 72 2 Human 7.2 pKi = 7.2 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 436 18 1 4 7.1 CCCCCCCCCCCCCCCCCC(=O)OC[C@@H]1CC(F)P(=O)(O)O1 10.1021/jm060351+
CHEMBL210117 78053 0 None 72 2 Human 7.2 pKi = 7.2 Functional
Activity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assayActivity at human LPA1 receptor expressed in RH7777 cells by calcium mobilization assay
ChEMBL 436 18 1 4 7.1 CCCCCCCCCCCCCCCCCC(=O)OC[C@@H]1CC(F)P(=O)(O)O1 10.1021/jm060351+
44325681 106868 0 None -2 2 Human 7.1 pKi = 7.1 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 626 23 4 4 9.1 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(Oc2cc3ccccc3[nH]2)cc1 10.1016/j.bmcl.2004.03.076
CHEMBL314554 106868 0 None -2 2 Human 7.1 pKi = 7.1 Functional
In vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell linesIn vitro ability to antagonize LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 1 in HEK293T cell lines
ChEMBL 626 23 4 4 9.1 CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(Oc2cc3ccccc3[nH]2)cc1 10.1016/j.bmcl.2004.03.076
90665720 109239 0 None - 0 Human 7.1 pKi = 7.1 Functional
Competitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation countingCompetitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation counting
ChEMBL 702 27 3 6 9.0 CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2cc(OCC(F)(F)F)ccn2)cc1 10.1039/c0md00273a
CHEMBL3218459 109239 0 None - 0 Human 7.1 pKi = 7.1 Functional
Competitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation countingCompetitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation counting
ChEMBL 702 27 3 6 9.0 CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP(=O)(O)O)Cc1ccc(OCc2cc(OCC(F)(F)F)ccn2)cc1 10.1039/c0md00273a
2913 346 0 None -8 2 Human 6.2 pEC50 = 6.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC 16892372
56947064 346 0 None -8 2 Human 6.2 pEC50 = 6.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC 16892372
CHEMBL3621962 346 0 None -8 2 Human 6.2 pEC50 = 6.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 452 22 2 4 6.3 CCCCCCCC/C=C\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC 16892372
11314 1193 0 None -25 3 Human 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 275 6 1 3 3.7 CCN([C@H](c1cccc2c1oc(c2C)CC)CO)CC 32409422
154733035 1193 0 None -25 3 Human 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 275 6 1 3 3.7 CCN([C@H](c1cccc2c1oc(c2C)CC)CO)CC 32409422
10074712 3694 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 18781939
10074712 3694 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 20729877
23701997 3694 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 18781939
23701997 3694 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 20729877
6984 3694 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 18781939
6984 3694 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 20729877
73755252 3694 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 18781939
73755252 3694 0 None -1000 2 Mouse 6.3 pEC50 = 6.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 500 19 1 6 6.7 CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(S[Na])O 20729877
10587 3877 4 None - 1 Human 6.6 pEC50 = 6.6 Functional
UnclassifiedUnclassified
Guide to Pharmacology 464 15 2 4 4.8 BrC[C@@H](OC(=O)CCCCCCCCCc1ccccc1)COP(=O)(O)O 31790581
145996523 3877 4 None - 1 Human 6.6 pEC50 = 6.6 Functional
UnclassifiedUnclassified
Guide to Pharmacology 464 15 2 4 4.8 BrC[C@@H](OC(=O)CCCCCCCCCc1ccccc1)COP(=O)(O)O 31790581
CHEMBL4646737 3877 4 None - 1 Human 6.6 pEC50 = 6.6 Functional
UnclassifiedUnclassified
Guide to Pharmacology 464 15 2 4 4.8 BrC[C@@H](OC(=O)CCCCCCCCCc1ccccc1)COP(=O)(O)O 31790581
2936 85 0 None -19 4 Human 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC(COP(=O)(O)O)CO 10922489
56947016 85 0 None -19 4 Human 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OC(COP(=O)(O)O)CO 10922489
17757220 2694 0 None -6 3 Mouse 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 405 19 3 3 5.2 CCCCCCCC/C=C/CCCCCCCC(=O)NCCOP(=O)(O)O 18781939
6982 2694 0 None -6 3 Mouse 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 405 19 3 3 5.2 CCCCCCCC/C=C/CCCCCCCC(=O)NCCOP(=O)(O)O 18781939
CHEMBL1574292 2694 0 None -6 3 Mouse 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 405 19 3 3 5.2 CCCCCCCC/C=C/CCCCCCCC(=O)NCCOP(=O)(O)O 18781939
6983 2898 0 None 1 4 Human 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 907 48 0 7 19.6 CCCCCCCC/C=C\CCCCCCCC(=O)OP(=O)(SC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC 16033271
6983 2898 0 None -1 4 Mouse 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 907 48 0 7 19.6 CCCCCCCC/C=C\CCCCCCCC(=O)OP(=O)(SC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC 20729877
73755251 2898 0 None 1 4 Human 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 907 48 0 7 19.6 CCCCCCCC/C=C\CCCCCCCC(=O)OP(=O)(SC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC 16033271
73755251 2898 0 None -1 4 Mouse 6.7 pEC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 907 48 0 7 19.6 CCCCCCCC/C=C\CCCCCCCC(=O)OP(=O)(SC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC 20729877
11313 1191 0 None 1 3 Human 7.5 pEC50 = 7.5 Functional
UnclassifiedUnclassified
Guide to Pharmacology 261 5 1 3 3.4 CCN([C@H](c1cccc2c1oc(c2C)C)CO)CC 32409422
154733034 1191 0 None 1 3 Human 7.5 pEC50 = 7.5 Functional
UnclassifiedUnclassified
Guide to Pharmacology 261 5 1 3 3.4 CCN([C@H](c1cccc2c1oc(c2C)C)CO)CC 32409422
2906 2340 18 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 18781939
2906 2340 18 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 20505096
2906 2340 18 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 8922387
5395 2340 18 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 18781939
5395 2340 18 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 20505096
5395 2340 18 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 8922387
5497152 2340 18 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 18781939
5497152 2340 18 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 20505096
5497152 2340 18 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 8922387
CHEMBL1222042 2340 18 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 18781939
CHEMBL1222042 2340 18 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 20505096
CHEMBL1222042 2340 18 None 1 12 Mouse 8.1 pEC50 = 8.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 436 20 3 5 5.0 CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COP(=O)(O)O)O 8922387
2905 388 49 None 1 7 Mouse 7.7 pEC50 None 7.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 490 7 2 5 6.9 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C 20649573
46240292 388 49 None 1 7 Mouse 7.7 pEC50 None 7.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 490 7 2 5 6.9 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C 20649573
CHEMBL3621966 388 49 None 1 7 Mouse 7.7 pEC50 None 7.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 490 7 2 5 6.9 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C 20649573
11785732 2919 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
FLIPR intracellular calcium mobilisation assayFLIPR intracellular calcium mobilisation assay
Guide to Pharmacology 521 11 2 7 4.4 COC(=O)c1cn(cc1CC(=O)O)C[C@@H]([C@@H](c1cc(OC)c(c(c1)OC)C)O)CC1Cc2c(C1)cccc2 26091040
8589 2919 0 None - 1 Human 7.6 pIC50 = 7.6 Functional
FLIPR intracellular calcium mobilisation assayFLIPR intracellular calcium mobilisation assay
Guide to Pharmacology 521 11 2 7 4.4 COC(=O)c1cn(cc1CC(=O)O)C[C@@H]([C@@H](c1cc(OC)c(c(c1)OC)C)O)CC1Cc2c(C1)cccc2 26091040
8590 2920 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
FLIPR intracellular calcium mobilisation assayFLIPR intracellular calcium mobilisation assay
Guide to Pharmacology 563 13 2 8 4.7 COC(=O)c1cn(cc1CCC(=O)O)C[C@@H]([C@@H](c1cc(OC)c(c(c1)OC)C(=O)C)O)CC1Cc2c(C1)cccc2 26091040
91799237 2920 0 None - 1 Human 7.7 pIC50 = 7.7 Functional
FLIPR intracellular calcium mobilisation assayFLIPR intracellular calcium mobilisation assay
Guide to Pharmacology 563 13 2 8 4.7 COC(=O)c1cn(cc1CCC(=O)O)C[C@@H]([C@@H](c1cc(OC)c(c(c1)OC)C(=O)C)O)CC1Cc2c(C1)cccc2 26091040
8588 2911 0 None - 1 Human 8.0 pIC50 = 8.0 Functional
FLIPR intracellular calcium mobilisation assayFLIPR intracellular calcium mobilisation assay
Guide to Pharmacology 518 11 2 6 4.8 COc1cc(cc(c1C)OC)[C@H]([C@@H](OC1Cc2c(C1)cccc2)COc1ccc(cc1)C1(CC1)C(=O)O)O 26091040
91799238 2911 0 None - 1 Human 8.0 pIC50 = 8.0 Functional
FLIPR intracellular calcium mobilisation assayFLIPR intracellular calcium mobilisation assay
Guide to Pharmacology 518 11 2 6 4.8 COc1cc(cc(c1C)OC)[C@H]([C@@H](OC1Cc2c(C1)cccc2)COc1ccc(cc1)C1(CC1)C(=O)O)O 26091040
16725999 728 1 None -9 2 Human 5.3 pIC50 = 5.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O 19509223
6985 728 1 None -9 2 Human 5.3 pIC50 = 5.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O 19509223
CHEMBL3621357 728 1 None -9 2 Human 5.3 pIC50 = 5.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O 19509223
24771260 428 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@@H](P(=O)(O)O)Br)O 19509223
6987 428 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@@H](P(=O)(O)O)Br)O 19509223
CHEMBL3621356 428 0 None - 1 Human 5.7 pIC50 = 5.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@@H](P(=O)(O)O)Br)O 19509223
46213949 372 47 None 5 2 Human 6.1 pIC50 = 6.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 21159750
6988 372 47 None 5 2 Human 6.1 pIC50 = 6.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 21159750
CHEMBL2182052 372 47 None 5 2 Human 6.1 pIC50 = 6.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 21159750
46213949 372 47 None -5 2 Mouse 6.1 pIC50 = 6.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 21159750
6988 372 47 None -5 2 Mouse 6.1 pIC50 = 6.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 21159750
CHEMBL2182052 372 47 None -5 2 Mouse 6.1 pIC50 = 6.1 Functional
UnclassifiedUnclassified
Guide to Pharmacology 456 7 2 5 6.3 OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C 21159750
24771259 3690 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@H](P(=O)(O)O)Br)O 19509223
6986 3690 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@H](P(=O)(O)O)Br)O 19509223
CHEMBL3621355 3690 0 None - 1 Human 6.2 pIC50 = 6.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 486 19 3 4 5.7 CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@H](P(=O)(O)O)Br)O 19509223
10367662 2173 91 None -1 5 Mouse 6.8 pIC50 = 6.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 14500756
2907 2173 91 None -1 5 Mouse 6.8 pIC50 = 6.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 14500756
CHEMBL361501 2173 91 None -1 5 Mouse 6.8 pIC50 = 6.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 474 9 2 6 6.3 OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C 14500756